



COMPANY OVERVIEW

Cerecor is a biopharmaceutical company developing innovative therapies at the cutting edge of science. Our pipeline, filled with forward-thinking ideas, propels us forward. We are driven to change the lives of patients with rare pediatric and orphan diseases.

RECENT NEWS

Cerecor Inc. Announces Closing of \$36.4 Million Public Offering of Common Stock and Pre-Funded Warrants

Jan 12 2021, 4:01 PM EST

Cerecor Inc. Announces Pricing of \$36.4 Million Public Offering of Common Stock and Pre-Funded Warrants

Jan 7 2021, 10:03 PM EST

STOCK OVERVIEW

Symbol	CERC
Exchange	Nasdaq
Market Cap	256.62m
Last Price	\$2.90
52-Week Range	\$1.52 - \$5.02

01/19/2021 04:00 PM EST

INVESTOR RELATIONS

ir@cerecor.com

MANAGEMENT TEAM

Michael Cola

Chief Executive Officer

Younok Dumortier Shin, PhD, MBA

Chief Technology Officer

James A. Harrell, Jr.

Chief Commercial Officer

Dr. Garry Neil, MD

Chief Scientific Officer

Chris Sullivan

Interim Chief Financial Officer

H. Jeffrey Wilkins, MD

Chief Medical Officer

Lisa Hegg Ph.D.

Vice President Research and Development Programs and Project Management

Colleen Matkowski

Vice President Global Regulatory Affairs

CERECOR, INC.

540 Gaither Road
Suite 400
Rockville, MD 20850

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.